Vinpocetine Dietary Supplement: Vincamine Derivative - Dosage, Reviews

Vinpocetine 15mg is a dietary supplement containing vinpocetine, a derivative of vincamine extracted from periwinkle (Vinca minor L).

Because of its rheological properties, and action on cerebral blood flow and metabolism, it is primarily used for its neuroprotective effects and is one of the most sought-after supplements for brain nutrition.

Who is Vinpocetine 15mg aimed at?

Vinpocetine 15mg is of potential interest to several groups of people:

• those with recurrent memory problems;
• those affected by cerebral dysfunction;
• those wishing to increase their cerebral metabolism momentarily or permanently;
• those at high risk of cardiovascular problems;
• those suffering from presbycusis (age-related hearing loss);
• those regularly affected by tinnitus.

What benefits are offered by vinpocetine?

A number of studies have demonstrated the positive effects of vinpocetine on cognition, hearing and memory (1-3), with several mechanisms of action identified:

1. it increases blood flow to the brain (4-6) ;
2. it facilitates the supply of oxygen and glucose to brain cells (7) ;
3. it supports energy production in brain cell mitochondria;
4. it helps inhibit a substance called phosphodiesterase;
5. it helps increase production of neurotransmitters in the brain.

Two studies have shown that, once ingested, vinpocetine crosses the blood-brain barrier to enter the brain (8-9).

Other research has highlighted its antioxidant (10-11), vasodilatory (12), anti-inflammatory (13-14) and antithrombotic properties (15) which are likely to help reduce the risk of cardiovascular problems.

How should Vinpocetine 15mg be taken?

The amount of vinpocetine used in clinical trials varied from 20mg to 50mg a day, and was ideally spread across three doses. Taking 2-3 capsules of Vinpocetine 15mg (30-45mg) a day is therefore fully consistent with the doses examined.

It’s worth noting that vinpocetine is absorbed best by the body when taken with food(16).

Should I be aware of any contraindications before buying vinpocetine?

Vinpocetine plays a role in inhibiting blood platelets.

It is therefore not recommended for those suffering from bleeding disorders or who have had surgery.
Neither should it be taken alongside drugs or supplements which also affect platelet activity, such as high-dose garlic, ginkgo biloba or vitamin E supplements.

Vinpocetine has been used in many countries for over 30 years, particularly for treating neurological issues relating to cerebrovascular problems such as stroke and ischaemia. No serious side-effects have been found from taking it at therapeutic doses, including long-term use.

Vinpocetine is photosensitive and should therefore be stored away from light.

Finally, it’s worth considering other innovative nootropic supplements such as Sarcosine and Homotaurine.

Note : this product should not be used to replace a varied, balanced diet or healthy lifestyle. Follow the advice on use, the recommended daily dose and the use-by date. Not recommended for women who are pregnant or breastfeeding, or for children under 15. Keep out of young children’s reach. Store in a cool, dry place.

Updated : March 2019

1. Kiss B, Szpomy L. On the possible role of central monoaminergic systems in the central nervous systems actions of vinpocetine. Drug Dev Res. 1988;14:263–79.
2. Shibuya T, Sato K. Effects of vinpocetine on experimental brain ischemia, histological study of brain monoamines. Igaku No Ayumi. 1986;139:217–9.
3. Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology (Berl) 1990;101:147–59
4. Patyar, S., Prakash, A., Modi, M., Medhi, B., 2011. Role of vinpocetine in cerebrovascular diseases. Pharmacol. Rep. 63, 618–628.
5. Bonoczk, P., Gulyas, B., Adam-Vizi, V., Nemes, A., Karpati, E., Kiss, B., Kapas, M., Szantay, C., Koncz, I., Zelles, T., Vas, A., 2000. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull. 53, 245–254.
6. Zhang, L., Yang, L., 2015. Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: a review of the literature. Molecules 20, 335–347.
7. Szilagyi, G., Nagy, Z., Balkay, L., Boros, I., Emri, M., Lehel, S., Marian, T., Molnar, T., Szakall, S., Tron, L., Bereczki, D., Csiba, L., Fekete, I., Kerenyi, L., Galuska, L., Varga, J., Bonoczk, P., Vas, A., Gulyas, B., 2005. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J. Neurol. Sci. 229–230, 275–284.
8. Gulyas, B., Halldin, C., Sandell, J., Karlsson, P., Sovago, J., Karpati, E., Kiss, B., Vas, A., Cselenyi, Z., Farde, L., 2002a. PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. Acta Neurol. Scand. 106, 325–332
9. Gulyas, B., Halldin, C., Sovago, J., Sandell, J., Cselenyi, Z., Vas, A., Kiss, B., Karpati, E., Farde, L., 2002b. Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine. Eur. J. Nucl. Med. Mol. Imaging 29, 1031–1038.
10. Deshmukh, R., Sharma, V., Mehan, S., Sharma, N., Bedi, K.L., 2009. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine – a PDE1 inhibitor. Eur. J. Pharmacol. 620, 49–56.
11. Herrera-Mundo, N., Sitges, M., 2013. Vinpocetine and alpha-tocopherol prevent the increase in DA and oxidative stress induced by 3-NPA in striatum isolated nerve endings. J. Neurochem. 124, 233–240
12. Giachini, F.R., Lima, V.V., Carneiro, F.S., Tostes, R.C., Webb, R.C., 2011. Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1. Hypertension 57, 655–663.
13. Jeon, K.-I., Xu, X., Aizawa, T., Lim, J.H., Jono, H., Kwon, D.-S., Abe, J.-I., Berk, B.C., Li, J.- D., Yan, C., 2010. Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA 107, 9795–9800.
14. Medina, A.E., 2010. Vinpocetine as a potent antiinflammatory agent. Proc. Natl. Acad. Sci. USA 107, 9921–9922.
15. Yi-shuai Zhang, Jian-dong Li, and Chen Yan. An update on Vinpocetine: New discoveries and clinical implications, Eur J Pharmacol. 2018 Jan 15; 819: 30–34.
16. Lohmann A, Dingler E, Sommer W, et al. Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung. 1992;42:914-917.